State-of-the-Art Imaging in Human Chordoma of the Skull Base

被引:38
作者
Santegoeds R.G.C. [1 ]
Temel Y. [2 ]
Beckervordersandforth J.C. [3 ]
Van Overbeeke J.J. [2 ]
Hoeberigs C.M. [1 ]
机构
[1] Department of Radiology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht
[2] Department of Neurosurgery, Maastricht University Medical Center, Maastricht
[3] Department of Pathology, Maastricht University Medical Center, Maastricht
关键词
Benign notochordal cell tumour (BNCT); Chondrosarcoma; Chordoma; Computed tomography (CT); Diffusion-weighted imaging (DWI); Magnetic resonance imaging (MRI); Positron emission tomography (PET);
D O I
10.1007/s40134-018-0275-7
中图分类号
学科分类号
摘要
Purpose of Review: Chordoma are rare tumours of the axial skeleton which occur most often at the base of the skull and in the sacrum. Although chordoma are generally slow-growing lesions, the recurrence rate is high and the location makes it often difficult to treat. Both computed tomography (CT) and magnetic resonance imaging (MRI) are crucial in the initial diagnosis, treatment planning and post-treatment follow-up. Recent Findings: Basic MRI and CT characteristics of chordoma were described in the late 1980s and early 1990s. Since then, imaging techniques have evolved with increased resolution and new molecular imaging tools are rapidly evolving. New imaging tools have been developed not only to study anatomy, but also physiologic changes and characterization of tissue and assessment of tumour biology. Recent studies show the uptake of multiple PET tracers in chordoma, which may become an important aspect in the diagnosis, follow-up and personalized therapy. Summary: This review gives an overview of skull base chordoma histopathology, classic imaging characteristics, radiomics and state-of-the-art imaging techniques that are now emerging in diagnosis, treatment planning and disease monitoring of skull base chordoma. © 2018, The Author(s).
引用
收藏
相关论文
共 115 条
  • [1] Kyriakos M., Benign notochordal lesions of the axial skeleton: a review and current appraisal, Skelet Radiol, 40, 9, pp. 1141-1152, (2011)
  • [2] Yakkioui Y., van Overbeeke J.J., Santegoeds R., van Engeland M., Temel Y., Chordoma: the entity, Biochim Biophys Acta, 1846, 2, pp. 655-669, (2014)
  • [3] McMaster M.L., Goldstein A.M., Bromley C.M., Ishibe N., Parry D.M., Chordoma: incidence and survival patterns in the United States, 1973–1995, Cancer Causes Control, 12, 1, pp. 1-11, (2001)
  • [4] Lee I.J., Lee R.J., Fahim D.K., Prognostic factors and survival outcome in patients with chordoma in the United States: a population-based analysis, World Neurosurg, 104, pp. 346-355, (2017)
  • [5] Whelan J., McTiernan A., Cooper N., Wong Y.K., Francis M., Vernon S., Et al., Incidence and survival of malignant bone sarcomas in England 1979–2007, Int J Cancer, 131, 4, pp. E508-E517, (2012)
  • [6] Jones P.S., Aghi M.K., Muzikansky A., Shih H.A., Barker F.G., Curry W.T., Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database, J Clin Neurosci, 21, 9, pp. 1490-1496, (2014)
  • [7] Wu Z., Zhang J., Zhang L., Jia G., Tang J., Wang L., Et al., Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas-106 cases review in one institution, Neurosurg Rev, 33, 4, pp. 451-456, (2010)
  • [8] Walcott B.P., Nahed B.V., Mohyeldin A., Coumans J.V., Kahle K.T., Ferreira M.J., Chordoma: current concepts, management, and future directions, Lancet Oncol, 13, 2, pp. e69-e76, (2012)
  • [9] Stacchiotti S., Gronchi A., Fossati P., Akiyama T., Alapetite C., Baumann M., Et al., Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group, Ann Oncol, 28, 6, pp. 1230-1242, (2017)
  • [10] Rich T.A., Schiller A., Suit H.D., Mankin H.J., Clinical and pathologic review of 48 cases of chordoma, Cancer, 56, 1, pp. 182-187, (1985)